 I. Determine the feasibility of intraperitoneal IP cisplatin and intravenous IV paclitaxel followed by IP paclitaxel in patients with stage IIB, IIC, III, or IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. 